Contact Us
Drug Search Results
More Filters [+]

Capadenoson

Alternative Names: capadenoson
Latest Update: 2023-05-30
Latest Update Note: PubMed Publication

Product Description

Capadenoson (BAY 68-4986) is a nonnucleoside agonist for the A1 Adenosine Receptor (A1AR) and the A2BAR. Capadenoson has undergone two Phase IIa clinical trials, initially in patients with atrial fibrillation and subsequently in patients with stable angina. (Sourced from: https://drugs.ncats.io/drug/O519NVW73R)

Mechanisms of Action: ADORA1 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Capadenoson

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Angina Pectoris|Angina, Stable|Atrial Fibrillation

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2007-003619-30

P2

Completed

Atrial Fibrillation

2009-03-05

NCT00568945

P2

Completed

Atrial Fibrillation

2008-11-01

2007-000425-22

P2

Completed

Angina, Stable

2008-03-20

EudraCT 2007-000425-22

P2

Withdrawn

Angina Pectoris|Angina, Stable

None

Recent News Events

Date

Type

Title

05/30/2023

PubMed

 Investigation of adenosine A1 receptor-mediated β-arrestin 2 recruitment using a split-luciferase assay.

09/01/2021

PubMed

 Lack of efficacy of a partial adenosine A1 receptor agonist in neuropathic pain models in mice.

03/11/2021

PubMed

 Pharmacological Insights Into Safety and Efficacy Determinants for the Development of Adenosine Receptor Biased Agonists in the Treatment of Heart Failure.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions